Institutional PresentationJune/2015

2

Disclaimer

This release contains forward-looking statements that are exclusively related to the prospects of the business. its operating

and financial results. and prospects for growth. These data are merely projections and. as such. based exclusively on our

management's expectations for the future of the business and its continued access to capital to fund its business plan.

These forward-looking statements substantially depend on changing market conditions. government regulations.

competitive pressures. the performance of the Brazilian economy and the industry. among other factors. as well as the

risks shown in our filed disclosure documents. and are therefore subject to change without prior notice.

As a goal to maintain a correlation with the Financial Statements prepared by its external auditors. the considerations and

comments contained herein are prepared on a consolidated viewpoint of the economic group Hypermarcas. and not

necessarily individualized by the various legal entities that compose the group.

In addition. unaudited information herein reflects management's interpretation of information taken from its financial

statements and their respective adjustments. which were prepared in accordance with market practices and for the sole

purpose of a more detailed and specific analysis of our results. Therefore. these additional points and data must also be

analyzed and interpreted independently by shareholders and market agents. who should carry out their own analysis and

draw their own conclusions from the results reported herein. No data or interpretative analysis provided by our

management should be treated as a guarantee of future performance or results and are merely illustrative of our directors'

vision of our results.

Our management is not responsible for compliance or accuracy of the management financial data discussed in this report.

which must be considered as for informational purposes only. and should not override the analysis of our audited

consolidated financial statements for purposes of a decision to invest in our stock. or for any other purpose.2

Agenda

Hypermarcas snapshot

Pharma division

Consumer division

Financials

3

4

OTC

Branded generics

Generics

Dermocosmetics

Sweeteners

Condoms

Skin care

Nail polish

Adult diapers

Leadership position in key markets

55% 45%R$4.8 billionPHARMA

DIVISIONCONSUMER

DIVISION

67%33% R$3.0 billionPHARMA

DIVISION CONSUMERDIVISION

* 1Q15 LTM

Ne

t re

ven

ue

Gro

ss p

rofi

t

12.311.5

9.8 10.09.3

7.9 8.1

6.76.0 5.5 5.4

4.8

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

5

8.1

10.0

13.7

18.723.8

29.8

2000 2010 2020 2030 2040 2050

29

8%

Population: 203 MM

2003 2014

55%15%

38%

60%

7%25%

A/B

C

D/E

Population aging( % of 60+)

Unemployment rate(%; LTM Average)

Brazilian market

SOURCE: IPEA (http://www.ipeadata.gov.br) and IBGE

Real monthly income(R$ K; Nov 2014; LTM Average)

Social class distribution

1.56

1.57 1.601.67 1.73

1.80 1.841.93 1.98

2.07 2.102.17

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

39

%

World: 8.3%

-17.0%

-12.0%

-7.0%

-2.0%

3.0%

8.0%

13.0%

18.0%

23.0%

28.0%

jun

-09

set-

09

dez

-09

mar

-10

jun

-10

set-

10

dez

-10

mar

-11

jun

-11

set-

11

dez

-11

mar

-12

jun

-12

set-

12

dez

-12

mar

-13

jun

-13

set-

13

dez

-13

mar

-14

jun

-14

set-

14

dez

-14

mar

-15

Broad retail Pharma and cosmetics Supermarkets Automobiles Construction materials

Retail sales

SOURCE: IBGE

Growth(6m YoY Moving Average)

1st United States

2nd China

3rd Japan

4th Germany

5th USD 36 B

6th France

7th Italy

7

Trends

Brazil pharma market overview

Ranking 2014*

1st United States

2nd China

3rd Japan

4th Germany

5th France

6th USD 24B

7th Italy

• Low levels of disease treatments

• Underdeveloped health system

• Aging of population

• Still low penetration of generics (25%* of the Pharma Market)

• Peak in economically active population

* IMS Health

Ranking 2019*

Market Expected Growth (2014-2019): 8.3% p.a.

8

OTC RX Generics

#1

#2 EMS

#3 Sanofi

#2 Novartis

#1

#3 Aché

#1 EMS

#2 Sanofi

#3

14.8%

9.3%

7.1%

7.1%

7.2%

7.0%

28.7%

16.0%

13.2%

Market share

Relevant positioning in all markets

Source: IMS Health PMB April/2015.

¹ LTM April average² May 15, 2015

632.1 MM Shares

20.1%

14.8%

6.0%

59.1%

Igarapava Participações S.A.

Maiorem S.A. de C.V

Other Controlling Shareholders

Free Float

(Founder)

• Sao Paulo Stock Exchange: - HYPE3- BRHYPEACNOR0

• Ibovespa Index Ranking: 29/70

• Trade volume¹: 2.4 MM shares/day

• ADR (HYPMY)²: 10.3 MM shares outstanding

SOURCE: BM&F Bovespa and Hypermarcas9

Ownership and listings

Ownership structure Listings

Agenda

Hypermarcas snapshot

Pharma division

Consumer division

Financials

10

11

41%

6%21%

12%

20%

OTC

BrandedGenerics(Similars)

RX

Generics

Dermocosmetics

Most diversified companyWith strong position in all segments

SOURCE: IMS Health; Company Data

1Q15 LTM revenuebreakdown

ShareRanking

OTC 14%

Branded Generics

24%

Generics 13%

Skincare 12%

Leading brands

Market share evolution – Pharma

12 Source: IMS Health – PMB.

9.2%9.3%

9.4%9.5%

9.9%10.0%

10.2%

10.6%

2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15

13

OTC: Traditional and well-established brands

Flu

Analgesics

Gastric

Other

1954 1958 1958 1961 1965

1933 1939 1958 1989 1993

1956 1965 1966 1970 1974

1904 1940 1956 1957 1967

14

Market coverage expansion plan

51%

65%

50%

31%

27%

15%

28%

36%

Total market

Generics

OTC

RX

Average 51% Average 78%

78%

80%

78%

67%

Existing productsPriority gaps

Market coverage

expansion plan

through new

products

Market coverage¹ by segment

¹ % of molecule markets in which Hypermarcas competes, IMS Health – PMB.

105

8291

123

5445

5943

51

88

120

200

2011 2012 2013 2014 YTD

# Filed # Approved # Pipeline(cumulative since 2011)

Strong focus on entering new markets and strengthening the portfolio

15

Innovation pipeline – Pharma

Source: Company’s data. Dec/2014

• Structured area

• Potential products

already in

negotiation

Partnership

accelerationStrategic

alliances

Clone

project

Internal

development

• Focus/prioritization

• Structure

increase

• New RDC

• Several products/ filed

presentations

• Better opportunity for

generics and branded

generics

• Pipeline in the

wholesale

• Prospecting initiated

How to fill the GAP?

16

Operations: High Scale, Modern Plant and Low Costs

Operations Network

17

MANUFACTURING DISTRIBUTION

• Largest distribution center in Brazil

• “Greenfield”, tailored to pharma

• High Scale: 50 thousand pallet positions in 37 thousand m²

• Largest site in Brazil• Diversified dosage forms: solids,

liquids, injectables, among others

• Modern facilities

• High Scale: Over 10 billion pills/year

• Lowest cost producer

• “1 site only”

• Low labor cost

• Logistics hub

• Fiscal incentives

• Non-unionized

Agenda

Hypermarcas snapshot

Pharma division

Consumer division

Financials

18

Ranking Share

Condoms 50%

Sweeteners 56%

Adult Diapers 30%

Skin Care 40%

Nail Polish 30%

Shaving Cream 41%

19 SOURCE: Nielsen Retail Index and Company Data

Portfolio of consumer brands

21%

40%

39%

Disposables(DPP)

Personal Care

Health

1Q15 LTM revenuebreakdown

7.6%7.7%

7.9%

8.2%8.1%

8.5%8.6%

Jan-Feb/14 Mar-Apr/14 May-Jun/14 Jul-Aug/14 Sept-Oct/14Nov-Dec/14 Jan-Feb/15

Source: Nielsen Retail Index. Value share.

Market share evolution - Consumer

20

Agenda

Hypermarcas snapshot

Pharma division

Consumer division

Financials

21

3,325

3,874

4,259

4,680

4,809

2011 2012 2013 2014 1Q15 LTM

Net revenue

22

1,684 1,7981,930 2,096 2,163

2011 2012 2013 2014 1Q15 LTM

Consumer

1,640

2,0762,329

2,584 2,646

2011 2012 2013 2014 1Q15 LTM

Pharma

Net revenue(R$ Million)

CAGR (2011-1Q15 LTM): 8.0%

CAGR (2011-1Q15 LTM): 15.9%

CAGR (2011-1Q15 LTM): 12.0%

27.4%

23.7%22.7%

21.1% 20.7%

2011 2012 2013 2014 1Q15LTM

23

Gross margin(%)

SG&A ex-marketing(%)

Marketing(%)

Gross margin and expenses

60.3%

62.2%

64.5%63.7%

63.1%

2011 2012 2013 2014 1Q15LTM

19.0% 18.3%19.6%

21.0% 20.8%

2011 2012 2013 2014 1Q15LTM

+2.8 pp

+1.8 pp

-6.7 pp

12.1%

16.8%

40.6%

Net revenue Adjusted EBITDA Net income*

CAGR(2011-14)

Acceleration of financial indicators

24 * CAGR 2012-14

Tax Credits from Income tax losses carry-

forward credits ²

(R$ Thousand)

ConsolidatedSeptember

30, 2014

• Explanatory Note

25

EV/EBITDAP/E Cash flow

Company’s main tax shields

Returns

Reason

1 Hypermarcas 2 1Q15 financial statements – explanatory note 21 (a)

Effect

Net income

Informationsource

Possible analysis impacts

Goodwill amortization ¹

• Acquisitions

• Earnings Release(Remaining Goodwill Amort. for Tax Purposes)

• Company´s Net Income

• Reduces Net Income for Tax Purposes• Reduces tax payment up to 30% in a

given year

• Goodwill Amortization

1Q15

26

EV/EBITDAP/E Cash flow

Company’s main tax shields

Returns

Reason

2 1Q15 financial statements – explanatory note 13

Effect

Net incomePossible analysis impacts

Tax credits¹

• Withhold tax from financial investments

• Tax credits from acquisitions

• Balance sheet

• Can be used to offset tax payments

Phone: +55 (11) 3627-4242

ir@hypermarcas.com.br

www.hypermarcas.com.br/ir

Contact data

27